| scholarly article | Q13442814 |
| P2093 | author name string | Rafflenbeul W | |
| Daniel WG | |||
| Gulba DC | |||
| Jost S | |||
| Lichtlen PR | |||
| Barthels M | |||
| Hecker H | |||
| Westhoff-Bleck M | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombolysis | Q1931577 |
| P304 | page(s) | 937-944 | |
| P577 | publication date | 1991-03-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy | |
| P478 | volume | 83 |
| Q28193615 | Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase |
| Q34748832 | Administration of glycoprotein IIb-IIIa inhibitors in patients with ST-segment elevation myocardial infarction |
| Q54088756 | Association of plasma levels of activated protein C with recanalization of the infarct-related coronary artery after thrombolytic therapy in acute myocardial infarction. |
| Q35687099 | Current status of thrombolytic therapy in acute myocardial infarction |
| Q46607639 | Development of an infection-resistant, bioactive wound dressing surface |
| Q35224506 | Dynamics in Thrombus Formation |
| Q44392523 | Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model |
| Q30785107 | Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials |
| Q56945403 | Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction |
| Q75243251 | Factor XII-dependent increases in thrombin activity induce carboxypeptidase-mediated attenuation of pharmacological fibrinolysis |
| Q74715955 | Failed coronary thrombolysis |
| Q34071792 | Failed thrombolysis in myocardial infarction |
| Q74098998 | Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction |
| Q74471668 | Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction |
| Q71551077 | Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group |
| Q40433419 | From the experimental myocardial infarction to the clinical acute myocardial infarction: limitations of thrombolytic therapy |
| Q28193157 | Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction |
| Q73295945 | Guidelines for the Management of Patients with Acute Myocardial Infarction |
| Q40433776 | Heparin as adjunctive therapy to coronary thrombolysis in acute myocardial infarction |
| Q35219807 | Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK |
| Q40466073 | Hirudin and Excess Bleeding Implications For Future Use |
| Q74267651 | Human platelet activation by thrombolytic agents: effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression |
| Q73286053 | Improving the Efficacy and Stability of Coronary Reperfusion Following Thrombolysis: Exploring the Thrombin Hypothesis |
| Q43942828 | Influence on coagulation activity by subcutaneous LMW heparin as an adjuvant treatment to fibrinolysis in acute myocardial infarction |
| Q40405209 | Interactions between endothelial secretogogues |
| Q73364768 | Issues Regarding the Use of Heparin Following Streptokinase Therapy |
| Q33801932 | Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know |
| Q71297329 | Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty |
| Q47957674 | Mechanism of rethrombosis after thrombolytic therapy: angioscopic findings and investigation of the coagulation system in dogs |
| Q36731145 | Monitoring thrombolytic therapy |
| Q61910236 | No effect of tranexamic acid on platelet function and thrombin generation (ETAPlaT) in postpartum haemorrhage: a randomised placebo-controlled trial. |
| Q73295821 | Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal |
| Q36840306 | Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease |
| Q73295940 | Platelet Activity in the Early Stage of Acute Myocardial Infarction: Relation to Time of Presentation, Treatment with Either Tissue Plasminogen Activator or Streptokinase and Cyclooxygenase Inhibition |
| Q34027520 | Platelet activation in acute myocardial infarction and the rationale for combination therapy |
| Q67485368 | Prolonged Coagulation Instability is Associated with a Higher‐dose Regimen of Tissue‐type Plasminogen Activator in Patients with Acute Myocardial Infraction |
| Q36255748 | Recurrent myocardial ischemia following thrombolytic therapy: guidelines for practicing clinicians |
| Q73551754 | Relationship between serum lipoprotein(a) level and thrombin generation to the circadian variation in onset of acute myocardial infarction |
| Q28166387 | Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis |
| Q73030430 | Selective thrombolysis in acute deep vein thrombosis: evaluation of adjuvant therapy in vivo |
| Q71870048 | Sequential combination thrombolytic therapy for acute myocardial infarction: results of the pro-urokinase and t-PA enhancement of thrombolysis (PATENT) trial |
| Q73745201 | Sequestrated thrombolysis: comparative evaluation in vivo |
| Q36971773 | Spontaneous coronary thrombosis following thrombolytic therapy for acute cardiovascular accident and stroke: a case study |
| Q52131991 | The Association of Anticoagulant Protein Concentrations with Acute Myocardial Infarction in the Thromholysis in Myocardial Infarction Phase II (TIMI II) Trial. |
| Q73365792 | The TIMI 9b and GUSTO IIb Trials and the "Thrombin Hypothesis" |
| Q34376928 | The thrombolytic paradox |
| Q73681259 | Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023) |
| Q56945190 | Thrombin Generation, Inhibition and Clinical Outcomes in Patients With Acute Myocardial Infarction Treated With Thrombolytic Therapy and Heparin: Results From the GUSTO-I Trial fn1fn1This study was supported by Genentech, Inc., South San Francisco, C |
| Q45746656 | Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome |
| Q73681264 | Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine |
| Q73321594 | Thrombogenesis and fibrinolysis in acute coronary syndromes. Important facets of a prothrombotic or hypercoagulable state? |
| Q53015487 | Thrombolysis in thromboembolic diseases. |
| Q40735993 | Thrombolytic retreatment with tissue plasminogen activator for threatened reinfarction and thrombotic coronary reocclusion |
| Q73665620 | Thrombolytic therapy and proteolysis of factor V |
| Q36721982 | Vessel Wall-Related Risk Factors in Acute Vascular Events |
Search more.